Open Medicine Institute to Use Affymetrix Arrays to Develop Tests for Chronic Fatigue Syndrome | GenomeWeb

NEW YORK (GenomeWeb) — The Open Medicine Institute said last week that it will use Affymetrix expression microarrays to develop tests to diagnose and aid in the treatment of myalgic encephalomyelitis and chronic fatigue syndrome.

In addition, Mountain View, Calif.-based OMI, which aims to improve healthcare by using new approaches and technologies, said that it has become an Affymetrix certified service provider and will use the platform to develop diagnostics for other diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.